S&P 500   4,330.00
DOW   34,070.42
QQQ   357.86
3 Compelling Reasons to Start Buying Undervalued Amazon
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
Stock market today: World shares are mixed, Chinese markets surge, after latest retreat on Wall St
Analysts Recommend These Mining Stocks Before Metal Prices Rally
The Strategic Gold Play You Haven't Heard About (Ad)
FedEx, Greenbrier rise; Cisco Systems, KB Home fall, Thursday, 9/21/2023
Turkey’s central bank hikes interest rates again in further shift in economic policies
The Strategic Gold Play You Haven't Heard About (Ad)
The average long-term US mortgage rate edged up to 7.19% this week, slightly below its 2023 high
Renowned Federal Judge, 96, Faces Yearlong Suspension For Refusing to Retire
S&P 500   4,330.00
DOW   34,070.42
QQQ   357.86
3 Compelling Reasons to Start Buying Undervalued Amazon
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
Stock market today: World shares are mixed, Chinese markets surge, after latest retreat on Wall St
Analysts Recommend These Mining Stocks Before Metal Prices Rally
The Strategic Gold Play You Haven't Heard About (Ad)
FedEx, Greenbrier rise; Cisco Systems, KB Home fall, Thursday, 9/21/2023
Turkey’s central bank hikes interest rates again in further shift in economic policies
The Strategic Gold Play You Haven't Heard About (Ad)
The average long-term US mortgage rate edged up to 7.19% this week, slightly below its 2023 high
Renowned Federal Judge, 96, Faces Yearlong Suspension For Refusing to Retire
S&P 500   4,330.00
DOW   34,070.42
QQQ   357.86
3 Compelling Reasons to Start Buying Undervalued Amazon
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
Stock market today: World shares are mixed, Chinese markets surge, after latest retreat on Wall St
Analysts Recommend These Mining Stocks Before Metal Prices Rally
The Strategic Gold Play You Haven't Heard About (Ad)
FedEx, Greenbrier rise; Cisco Systems, KB Home fall, Thursday, 9/21/2023
Turkey’s central bank hikes interest rates again in further shift in economic policies
The Strategic Gold Play You Haven't Heard About (Ad)
The average long-term US mortgage rate edged up to 7.19% this week, slightly below its 2023 high
Renowned Federal Judge, 96, Faces Yearlong Suspension For Refusing to Retire
S&P 500   4,330.00
DOW   34,070.42
QQQ   357.86
3 Compelling Reasons to Start Buying Undervalued Amazon
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
Stock market today: World shares are mixed, Chinese markets surge, after latest retreat on Wall St
Analysts Recommend These Mining Stocks Before Metal Prices Rally
The Strategic Gold Play You Haven't Heard About (Ad)
FedEx, Greenbrier rise; Cisco Systems, KB Home fall, Thursday, 9/21/2023
Turkey’s central bank hikes interest rates again in further shift in economic policies
The Strategic Gold Play You Haven't Heard About (Ad)
The average long-term US mortgage rate edged up to 7.19% this week, slightly below its 2023 high
Renowned Federal Judge, 96, Faces Yearlong Suspension For Refusing to Retire
NASDAQ:SNTI

Senti Biosciences (SNTI) Stock Forecast, Price & News

$0.52
+0.05 (+10.62%)
(As of 09/21/2023 ET)
Compare
Today's Range
$0.47
$0.55
50-Day Range
$0.45
$0.99
52-Week Range
$0.38
$8.77
Volume
55,241 shs
Average Volume
61,441 shs
Market Capitalization
$23.21 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.00

Senti Biosciences MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
667.8% Upside
$4.00 Price Target
Short Interest
Healthy
1.53% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.63) to ($1.12) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.96 out of 5 stars

Medical Sector

625th out of 965 stocks

Biological Products, Except Diagnostic Industry

96th out of 161 stocks


SNTI stock logo

About Senti Biosciences (NASDAQ:SNTI) Stock

Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

SNTI Price History

SNTI Stock News Headlines

The Strategic Gold Play You Haven't Heard About
Experts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure.
The Strategic Gold Play You Haven't Heard About
Experts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure.
Expert Ratings for Senti Biosciences
See More Headlines
Receive SNTI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Senti Biosciences and its competitors with MarketBeat's FREE daily newsletter.

SNTI Company Calendar

Last Earnings
8/11/2023
Today
9/22/2023
Next Earnings (Estimated)
11/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SNTI
Fax
N/A
Employees
122
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$4.00
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+667.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

Net Income
$-58,210,000.00
Net Margins
-1,785.30%
Pretax Margin
-1,785.30%

Debt

Sales & Book Value

Annual Sales
$3.05 million
Book Value
$2.90 per share

Miscellaneous

Free Float
38,977,000
Market Cap
$23.21 million
Optionable
Not Optionable
Beta
2.32
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Timothy K. Lu M.D. (Age 42)
    Ph.D., Co-founder, CEO, Pres & Director
    Comp: $811.26k
  • Dr. James J. Collins Ph.D. (Age 57)
    Scientific Co-Founder, Chairperson of Scientific Advisory Board & Independent Director
    Comp: $41.49k
  • Dr. Deborah A. Knobelman Ph.D. (Age 49)
    CFO, Head of Corp. Devel. & Treasurer
    Comp: $600.22k
  • Ms. Susan D. Berland (Age 68)
    Sr. Financial Exec. & Independent Director
    Comp: $54.23k
  • Dr. Kanya Rajangam M.D. (Age 50)
    Ph.D., Head of R&D and Chief Medical Officer
    Comp: $679.71k
  • Dr. Wilson Wong Ph.D.
    Scientific Co-Founder & Member of Scientific Advisory Board
  • Susan Kahlert
    Controller













SNTI Stock - Frequently Asked Questions

Should I buy or sell Senti Biosciences stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Senti Biosciences in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" SNTI shares.
View SNTI analyst ratings
or view top-rated stocks.

What is Senti Biosciences' stock price forecast for 2023?

4 brokerages have issued twelve-month target prices for Senti Biosciences' shares. Their SNTI share price forecasts range from $2.00 to $6.00. On average, they anticipate the company's share price to reach $4.00 in the next year. This suggests a possible upside of 667.8% from the stock's current price.
View analysts price targets for SNTI
or view top-rated stocks among Wall Street analysts.

How have SNTI shares performed in 2023?

Senti Biosciences' stock was trading at $1.41 on January 1st, 2023. Since then, SNTI shares have decreased by 63.0% and is now trading at $0.5210.
View the best growth stocks for 2023 here
.

When is Senti Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our SNTI earnings forecast
.

How were Senti Biosciences' earnings last quarter?

Senti Biosciences, Inc. (NASDAQ:SNTI) posted its quarterly earnings data on Friday, August, 11th. The company reported ($0.42) EPS for the quarter, topping analysts' consensus estimates of ($0.48) by $0.06. The firm had revenue of $0.94 million for the quarter, compared to the consensus estimate of $1.29 million. Senti Biosciences had a negative net margin of 1,785.30% and a negative trailing twelve-month return on equity of 60.56%.

What ETF holds Senti Biosciences' stock ?

ARK Genomic Revolution ETF holds 1,882,161 shares of SNTI stock, representing 0.08% of its portfolio.

What is Senti Biosciences' stock symbol?

Senti Biosciences trades on the NASDAQ under the ticker symbol "SNTI."

Who are Senti Biosciences' major shareholders?

Senti Biosciences' stock is owned by a number of institutional and retail investors. Top institutional investors include ARK Investment Management LLC (4.14%) and Triatomic Management LP (0.67%).
View institutional ownership trends
.

How do I buy shares of Senti Biosciences?

Shares of SNTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Senti Biosciences' stock price today?

One share of SNTI stock can currently be purchased for approximately $0.52.

How much money does Senti Biosciences make?

Senti Biosciences (NASDAQ:SNTI) has a market capitalization of $23.21 million and generates $3.05 million in revenue each year. The company earns $-58,210,000.00 in net income (profit) each year or ($1.64) on an earnings per share basis.

How many employees does Senti Biosciences have?

The company employs 122 workers across the globe.

How can I contact Senti Biosciences?

Senti Biosciences' mailing address is 2875 EL CAMINO REAL, REDWOOD CITY CA, 94061. The official website for the company is www.sentibio.com. The company can be reached via phone at 650-239-2030 or via email at irbd@dspc.bio.

This page (NASDAQ:SNTI) was last updated on 9/22/2023 by MarketBeat.com Staff

My Account -